Protalix BioTherapeutics, Inc. financial data

Symbol
PLX on NYSE
Industry
Biological Products, (No Diagnostic Substances)
Location
2 University Plaza, Suite 100, Hackensack, NJ
State of incorporation
DE
Fiscal year end
December 31
Former names
ORTHODONTIX INC (to 2/22/2007), EMBASSY ACQUISITION CORP (to 3/31/1998)
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 148 % -21.6%
Quick Ratio 43.5 % -27.7%
Debt-to-equity 163 % -52.2%
Return On Equity -30.9 % -149%
Return On Assets -11.7 % -182%
Operating Margin -19.5 % -191%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 73.6M shares +0.93%
Common Stock, Shares, Outstanding 73M shares +35.6%
Entity Public Float 139M USD +167%
Common Stock, Value, Issued 73K USD +35.2%
Weighted Average Number of Shares Outstanding, Basic 73.5M shares +1.75%
Weighted Average Number of Shares Outstanding, Diluted 81.2M shares -3.06%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 45.7M USD -28.2%
Cost of Revenue 29.3M USD +77.3%
Research and Development Expense 11.9M USD -39.1%
Operating Income (Loss) -8.91M USD -166%
Nonoperating Income (Expense) -681K USD +62.1%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -9.59M USD -181%
Income Tax Expense (Benefit) 18K USD +356%
Net Income (Loss) Attributable to Parent -9.61M USD -190%
Earnings Per Share, Basic -0.14 USD/shares -208%
Earnings Per Share, Diluted -0.09 USD/shares -325%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 27.4M USD +34.3%
Accounts Receivable, after Allowance for Credit Loss, Current 2.2M USD -75.4%
Inventory, Net 17.2M USD -20.3%
Other Assets, Current 1.05M USD -6.67%
Assets, Current 47.9M USD -34.1%
Deferred Income Tax Assets, Net 2.86M USD -7.63%
Property, Plant and Equipment, Net 4.65M USD -0.77%
Operating Lease, Right-of-Use Asset 5.65M USD -4.57%
Assets 61.6M USD -29.7%
Accounts Payable, Current 19.6M USD +4.47%
Employee-related Liabilities, Current 1.25M USD +0.97%
Accrued Liabilities, Current 8.34M USD -9.81%
Contract with Customer, Liability, Current 12.7M USD
Liabilities, Current 24.2M USD -44.1%
Contract with Customer, Liability, Noncurrent 0 USD -100%
Operating Lease, Liability, Noncurrent 4.18M USD -7.24%
Liabilities 29.1M USD -40.9%
Retained Earnings (Accumulated Deficit) 382M USD
Stockholders' Equity Attributable to Parent 32.4M USD -15.2%
Liabilities and Equity 61.6M USD -29.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 4.19M USD
Net Cash Provided by (Used in) Financing Activities 14.2M USD
Net Cash Provided by (Used in) Investing Activities -606K USD -113%
Common Stock, Shares Authorized 185M shares 0%
Common Stock, Shares, Issued 73M shares +35.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3.58M USD -77.6%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 27.4M USD +34.3%
Interest Paid, Excluding Capitalized Interest, Operating Activities 766K USD -28.9%
Deferred Tax Assets, Valuation Allowance 51.6M USD -11.8%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure
Operating Lease, Liability 6.03M USD +14.1%
Depreciation 322K USD +15%
Payments to Acquire Property, Plant, and Equipment 598K USD +141%
Lessee, Operating Lease, Liability, to be Paid 9.03M USD +7.28%
Property, Plant and Equipment, Gross 39.7M USD +3.72%
Operating Lease, Liability, Current 1.51M USD +14.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.4M USD +44.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.41M USD +26%
Operating Lease, Weighted Average Discount Rate, Percent 0.13 pure 0%
Deferred Income Tax Expense (Benefit) 443K USD +1066%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3M USD -4.15%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.13M USD +16.8%
Deferred Tax Assets, Operating Loss Carryforwards 51.5M USD -4.85%
Current Income Tax Expense (Benefit) 164K USD +72.6%
Unrecognized Tax Benefits 805K USD +51.9%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.04M USD +20.7%
Deferred Tax Assets, Net of Valuation Allowance 3.09M USD